---
layout: default
title: Alpha -Tocopherol Ascorbic Acid Banana Beta Carote
parent: Model Prediction Only (L5)
nav_order: 246
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Ascorbic Acid Banana Beta Carote
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Multi-component Natural Supplement Formulation: Insufficient Assessment Data, Cannot Proceed with Drug Repurposing Analysis

---

## One-Sentence Summary

This candidate is a multi-component supplement formulation composed of eight natural ingredients (α-tocopherol, ascorbic acid, banana, β-carotene, Houttuynia cordata, inulin, nattokinase, rutin), **not a single chemical drug**, and has not obtained any drug license in Taiwan to date. The TxGNN model **failed to generate any predicted indications**, primarily because the multi-component formulation cannot be mapped to DrugBank knowledge graph nodes, compounded by the lack of DrugBank ID and original indication data; this assessment **cannot proceed to substantive analysis phase**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Ingredient composition | α-tocopherol / ascorbic acid / banana / β-carotene / Houttuynia cordata / inulin / nattokinase / rutin |
| Original indication | No data |
| Predicted new indication | **None** (TxGNN unable to map; no prediction generated) |
| TxGNN prediction score | Not applicable |
| Evidence level | **L5** (model prediction failed; no supporting actual research) |
| Taiwan market status | ✗ Not marketed (0 drug licenses) |
| Number of licenses | 0 |
| Recommended decision | **Hold** |

---

## Why is This Prediction Reasonable?

This product is not a traditional single-entity drug, but rather a multi-component formulation composed of eight natural active substances from diverse sources:

- **Antioxidant vitamins**: α-tocopherol (vitamin E), ascorbic acid (vitamin C), β-carotene (vitamin A precursor), possessing properties for free radical scavenging and inhibition of oxidative stress.
- **Phytochemicals**: rutin (flavonoid with anti-inflammatory and vascular protective action), Houttuynia cordata (traditional herbal medicine with potential antimicrobial and immunomodulatory effects).
- **Functional food ingredients**: inulin (prebiotic fiber, modulates gut microbiota), banana (potassium source and carbohydrate), nattokinase (serine protease with fibrinolytic activity).

Because this product is a multi-component formulation and most of the ingredients are **food or health food materials** (not pharmaceutical drugs), the TxGNN knowledge graph—based on DrugBank drug nodes for network reasoning—cannot perform systematic mapping and prediction for such complex formulations.

Currently, the **`original_moa` field is empty**, precluding mechanistic association analysis. Should drug repurposing assessment be required, it is recommended to **segregate each single ingredient as an independent candidate for separate evaluation** (for example: independently assess the repositioning potential of Nattokinase or Rutin).

---

## Clinical Trial Evidence

No relevant clinical trial registrations are currently available (TxGNN generated no predicted indications, hence no targeted queries could be performed).

---

## Literature Evidence

No relevant literature is currently available (TxGNN generated no predicted indications, hence no targeted queries could be performed).

---

## US Market Information

This product holds no drug license in Taiwan and has no corresponding US FDA drug license data to display.

---

## Safety Considerations

Please refer to the individual product information sheets or safety data sheets of each ingredient for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This product is a multi-component natural formulation without drug licenses in Taiwan, with failed TxGNN mapping and no predicted indications. Under current technical conditions, **effective drug repurposing assessment cannot be performed**; advancement is not recommended until clear designation of individual active ingredients and drug-grade data are obtained.

**To proceed, the following is needed:**

- **Segregate candidate items**: Establish independent Evidence Packs for each of the eight ingredients, entering the TxGNN mapping workflow as individual INNs (priority recommendation: Nattokinase, Rutin, Houttuynia cordata)
- **Establish pharmaceutical identity**: Confirm whether each ingredient has a corresponding DrugBank ID (currently, no DrugBank ID is found for the overall formulation)
- **Supplement mechanism of action (MOA)**: Query DrugBank API for MOA data of each individual ingredient to resolve the DG002 data gap
- **Clarify regulatory classification**: Determine the classification of this product in Taiwan (pharmaceutical drug vs. health supplement vs. food), which will determine the applicable review pathway
- **Supplement TFDA product labels and warnings**: If relevant products exist, download and parse product labeling PDFs from the FDA website to extract safety information, resolving the DG001 blocking gap

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

